Induction of Tc1 response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg

被引:49
作者
Huang, Yin
Chen, Zhi
Jia, Hongyu
Wu, Wei
Zhong, Shigen
Zhou, Cheng
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Inst Infect Dis, Hangzhou 310003, Peoples R China
[2] Hangzhou Teachers Coll, Coll Med, Dept Immunol, Hangzhou 310018, Peoples R China
关键词
hepatitis B virus; dendritic cells; recombinant adenovirus; hepatitis B surface antigen; cytotoxic T; lymphocytes; interferon-gamma; interieukin-4; therapeutic vaccine; transgenic mice;
D O I
10.1016/j.clim.2006.01.015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
We evaluated the potential of dendritic cells (DCs) engineered to express antigen of hepatitis B virus (HBV) in priming Th/Tc and HBV-specific CTL responses in mice. Recombinant adenovirus expressing hepatitis B surface antigen (HBsAg) (Ad-S) was constructed, and bone marrow-derived DCs were transduced with Ad-S or pulsed with HBsAg protein. Mice were-S-transduced DCs or HBsAg-pulsed DCs or plasmid DNA encoding HBsAg injected with either Ad twice at 3-week intervals. We showed that adenovirus infection had no further effect on the phenotype, the ability to induce IFN-gamma-producing Th1/Tc1 response or the T cell stimulatory capacity of already mature DCs in vitro. We also showed that immunization with Ad-S-transduced DCs effectively induced Tc1 cells and HBsAg-specific CTLs in vivo and downregulated the circulating HBsAg and HBV DNA in HBV transgenic mice. Furthermore, these efficacies were stronger than that of HBsAg-pulsed DCs and plasmid DNA. Thus, DCs transduced with recombinant adenovirus may be a promising candidate for an effective CTL-based therapeutic vaccine against HBV. (c) 2006 Elsevier Inc. All. rights reserved.
引用
收藏
页码:280 / 290
页数:11
相关论文
共 52 条
[1]
Akbar Sk. Md. Fazle, 2004, Current Drug Targets - Infectious Disorders, V4, P93, DOI 10.2174/1568005043340885
[2]
Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers [J].
Akbar, SMF ;
Furukawa, S ;
Onji, M ;
Murata, Y ;
Niya, T ;
Kanno, S ;
Murakami, H ;
Horiike, N .
HEPATOLOGY RESEARCH, 2004, 29 (03) :136-141
[3]
Akbar SMF, 2004, INT J MOL MED, V14, P295
[4]
Dendritic cells and chronic hepatitis virus carriers [J].
Akbar, SMF ;
Horiike, N ;
Onji, M ;
Hino, O .
INTERVIROLOGY, 2001, 44 (04) :199-208
[5]
Arima S, 2003, INT J MOL MED, V11, P169
[6]
Dendritic cells as vectors for therapy [J].
Banchereau, J ;
Schuler-Thurner, B ;
Palucka, AK ;
Schuler, G .
CELL, 2001, 106 (03) :271-274
[7]
Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy [J].
Chamoto, K ;
Kosaka, A ;
Tsuji, T ;
Matsuzaki, J ;
Sato, T ;
Takeshima, T ;
Iwakabe, K ;
Togashi, Y ;
Koda, T ;
Nishimura, T .
CANCER SCIENCE, 2003, 94 (10) :924-928
[8]
Chen M, 2005, WORLD J GASTROENTERO, V11, P1806, DOI 10.3748/wjg.v11.i12.1806
[9]
DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy [J].
Chen, Z ;
Dehm, S ;
Bonham, K ;
Kamencic, H ;
Juurlink, B ;
Zhang, XS ;
Gordon, JR ;
Xiang, J .
CELLULAR IMMUNOLOGY, 2001, 214 (01) :60-71
[10]
CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333